Short Interest in ADMA Biologics, Inc. (NASDAQ:ADMA) Grows By 13.9%

ADMA Biologics, Inc. (NASDAQ:ADMA) saw a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 8,280,000 shares, a growth of 13.9% from the June 30th total of 7,270,000 shares. Based on an average daily volume of 3,130,000 shares, the days-to-cover ratio is currently 2.6 days.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Cantor Fitzgerald raised their target price on shares of ADMA Biologics from $10.00 to $15.00 and gave the company an “overweight” rating in a research note on Tuesday, July 9th. HC Wainwright increased their price target on shares of ADMA Biologics from $7.50 to $10.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Raymond James increased their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the company a “strong-buy” rating in a research report on Friday, May 10th. Finally, Mizuho increased their price target on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, ADMA Biologics has an average rating of “Buy” and a consensus price target of $12.25.

ADMA Biologics Stock Performance

Shares of NASDAQ:ADMA opened at $12.18 on Wednesday. The company has a debt-to-equity ratio of 0.91, a current ratio of 5.21 and a quick ratio of 1.86. The company has a market capitalization of $2.82 billion, a price-to-earnings ratio of -609.00 and a beta of 0.54. The firm’s 50 day simple moving average is $11.31 and its 200 day simple moving average is $7.98. ADMA Biologics has a fifty-two week low of $3.06 and a fifty-two week high of $14.03.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, May 9th. The biotechnology company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.05 by $0.03. The firm had revenue of $81.90 million for the quarter, compared to the consensus estimate of $77.28 million. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. The business’s quarterly revenue was up 43.9% on a year-over-year basis. During the same period last year, the company posted ($0.03) EPS. As a group, sell-side analysts forecast that ADMA Biologics will post 0.35 earnings per share for the current year.

Insider Activity

In other news, CEO Adam S. Grossman sold 100,000 shares of the firm’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $10.72, for a total value of $1,072,000.00. Following the transaction, the chief executive officer now owns 2,081,475 shares of the company’s stock, valued at approximately $22,313,412. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On ADMA Biologics

Hedge funds and other institutional investors have recently made changes to their positions in the company. LSV Asset Management bought a new position in shares of ADMA Biologics in the first quarter valued at $1,028,000. BNP Paribas Financial Markets grew its stake in shares of ADMA Biologics by 152.2% in the first quarter. BNP Paribas Financial Markets now owns 732,920 shares of the biotechnology company’s stock valued at $4,837,000 after buying an additional 442,315 shares in the last quarter. Alberta Investment Management Corp grew its stake in shares of ADMA Biologics by 32.4% in the fourth quarter. Alberta Investment Management Corp now owns 460,774 shares of the biotechnology company’s stock valued at $2,083,000 after buying an additional 112,831 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of ADMA Biologics by 90.7% in the first quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock valued at $7,717,000 after buying an additional 556,175 shares in the last quarter. Finally, Inspire Investing LLC grew its stake in shares of ADMA Biologics by 125.2% in the first quarter. Inspire Investing LLC now owns 189,303 shares of the biotechnology company’s stock valued at $1,249,000 after buying an additional 105,256 shares in the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.